Data Sheet (Cat.No.TMPS-00158)

TargetMol

TRAIL R2/DR5/TNFRSF10B Protein, Human, Recombinant

General Information

Synonyms:	TRICK2A;TRICKB;Tumor necrosis factor receptor superfamily member 10B;Death receptor 5; TRAIL receptor 2;KILLER/DR5;KILLER;TRAILR2;TRICK2B;TRAIL-R2;CD262;ZTNFR9;DR5; TNFRSF10B;TRICK2;TNF-related apoptosis-inducing ligand receptor 2
Protein Construction:	Glu52-Ser183
Species:	Human
Expression Host:	E. coli
Accession:	O14763
Molecular Weight:	14.8 kDa (Predicted)

QC Testing

Biological Activity:	Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/ml) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.
Purity:	> 97% as determined by SDS-PAGE; > 97% as determined by HPLC
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4.

Preparation and Storage

Reconstitution:

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml.

Stability & Storage:

Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling.1 The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells.2 TRAIL-R2 has been shown to be associated with a decrease in the

survival rates of breast cancer patients.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481